Physician profile
Barry Levinson
NPI 1043301641
$3,311.75
in general payments reported to CMS, 2019-2025
41 companies · $259 in 2025
The $259 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $935 · 2020: $405 · 2021: $337 · 2022: $688 · 2023: $614 · 2024: $74.09 · 2025: $259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $851 · Education: $95.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $851.31 |
| Education | $95.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $369.87 | 2019-2023 | Injectafer, Enhertu |
| Merck Sharp & Dohme LLC | $289.69 | 2019-2025 | Keytruda |
| Seagen INC. | $222.18 | 2019-2023 | Tukysa, Padcev |
| E.R. Squibb & Sons, L.L.C. | $199.24 | 2019-2025 | Opdivo |
| Celgene Corporation | $187.35 | 2020-2025 | Reblozyl |
| Bayer Healthcare Pharmaceuticals INC. | $153.97 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $151.43 | 2020-2024 | Libtayo |
| Amgen INC. | $148.24 | 2019-2023 | Lumakras, Kyprolis |
| Gilead Sciences, INC. | $136.57 | 2022-2025 | Trodelvy |
| Taiho Oncology, INC. | $127.91 | 2019-2022 | |
| Astellas Pharma US INC | $127.22 | 2019-2022 | |
| Pfizer INC. | $119.79 | 2019-2023 | |
| Lilly USA, LLC | $104.40 | 2019-2023 | Retevmo, Cyramza, Jaypirca |
| Astrazeneca Pharmaceuticals LP | $103.61 | 2019-2025 | |
| Incyte Corporation | $100.04 | 2019-2023 | Jakafi |
Show all 40 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Levinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.